SHOC2 plays an oncogenic or tumor-suppressive role by differentially targeting the MAPK and mTORC1 signals in liver cancer

Abstract

SHOC2 is a scaffold protein that activates the RAS-MAPK signal. Our recent study showed that SHOC2 is also a negative regulator of the mTORC1 signal in lung cancer cells. Whether and how SHOC2 differentially regulates the RAS-MAPK vs. the mTORC1 signals in liver cancer remains unknown. Here, we showed that SHOC2 is overexpressed in human liver cancer tissues, and SHOC2 overexpression promotes the growth and survival of liver cancer cells via activation of the RAS-MAPK signal, although the mTORC1 signal is inactivated. SHOC2 knockdown suppresses the growth of liver cancer cells mainly through inactivating the RAS-MAPK signal. Thus, in the cell culture models, SHOC2 regulation of growth is dependent of the RAS-MAPK but not the mTORC1 signal. Interestingly, in a mouse liver cancer model induced by diethylnitrosamine (DEN)-high-fat diet (HFD), hepatocyte-specific Shoc2 deletion inactivates the Ras-Mapk signal but has no effect in liver tumorigenesis. However, in the Pten loss-induced liver cancer model, Shoc2 deletion further activates mTorc1 without affecting the Ras-Mapk signal and promotes liver tumorigenesis. Collectively, it appears that SHOC2 could act as either an oncogene (via activating the MAPK signal) or a tumor suppressor (via inactivating the mTORC1 signal) in the manner dependent of the dominancy of the MAPK vs. mTORC1 signals.

Keywords

SHOC2 / RAS / mTORC1 / PTEN / liver cancer

References

[1] Selfors LM , Schutzman JL , Borland CZ , et al. soc-2 encodes a leucine-rich repeat protein implicated in fibroblast growth factor receptor signaling. Proc Natl Acad Sci USA 1998; 95: 6903- 8.

[2] Sieburth DS , Sun Q , Han M . SUR-8, a conserved Ras-binding protein with leucine-rich repeats, positively regulates Ras-mediated signaling in C. elegans. Cell 1998; 94: 119- 30.

[3] Jeoung M , Abdelmoti L , Jang ER , et al. Functional integration of the conserved domains of Shoc2 scaffold. PLoS One 2013; 8: e66067.

[4] Li W , Han M , Guan KL . The leucine-rich repeat protein SUR-8 enhances MAP kinase activation and forms a complex with Ras and Raf. Genes Dev 2000; 14: 895- 900.

[5] Dai P , Xiong WC , Mei L . Erbin inhibits RAF activation by disrupting the sur-8-Ras-Raf complex. J Biol Chem 2006; 281: 927- 33.

[6] Rodriguez-Viciana P , Oses-Prieto J , Burlingame A , et al. A phosphatase holoenzyme comprised of Shoc2/Sur8 and the catalytic subunit of PP1 functions as an M-Ras effector to modulate Raf activity. Mol Cell 2006; 22: 217- 30.

[7] Jang ER , Shi P , Bryant J , et al. HUWE1 is a molecular link controlling RAF-1 activity supported by the Shoc2 scaffold. Mol Cell Biol 2014; 34: 3579- 93.

[8] Xie CM , Tan M , Lin X-T , et al. The FBXW7-SHOC2-raptor axis controls the cross-talks between the RAS-ERK and mTORC1 signaling pathways. Cell Rep 2019; 26: 3037- 50.e4.

[9] Xie CM , Sun Y . The MTORC1-mediated autophagy is regulated by the FBXW7-SHOC2-RPTOR axis. Autophagy 2019; 15: 1470- 2.

[10] Cordeddu V , Di Schiavi E , Pennacchio LA , et al. Mutation of SHOC2 promotes aberrant protein N-myristoylation and causes Noonan-like syndrome with loose anagen hair. Nat Genet 2009; 41: 1022- 6.

[11] Young LC , Hartig N , Muñoz-Alegre M , et al. An MRAS, SHOC2, and SCRIB complex coordinates ERK pathway activation with polarity and tumorigenic growth. Mol Cell 2013; 52: 679- 92.

[12] Lee YM , Kaduwal S , Lee KH , et al. Sur8 mediates tumorigenesis and metastasis in colorectal cancer. Exp Mol Med 2016; 48: e249.

[13] Sulahian R , Kwon JJ , Walsh KH , et al. Synthetic lethal interaction of SHOC2 depletion with MEK inhibition in RAS-driven cancers. Cell Rep 2019; 29: 118- 34.e8.

[14] Geng W , Dong K , Pu Q , et al. SHOC2 is associated with the survival of breast cancer cells and has prognostic value for patients with breast cancer. Mol Med Rep 2020; 21: 867- 75.

[15] Lee KH , Jeong W-J , Cha P-H , et al. Stabilization of Sur8 via PKCalpha/delta degradation promotes transformation and migration of colorectal cancer cells. Oncotarget 2017; 8: 115596- 608.

[16] Jones GG , Del Río IB , Sari S , et al. SHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition in RAS-mutant cancers. Nat Commun 2019; 10: 2532.

[17] Kaduwal S , Jeong W-J , Park J-C , et al. Sur8/Shoc2 promotes cell motility and metastasis through activation of Ras-PI3K signaling. Oncotarget 2015; 6: 33091- 105.

[18] Jeoung M , Jang ER , Liu J , et al. Shoc2-tranduced ERK1/2 motility signals-Novel insights from functional genomics. Cell Signal 2016; 28: 448- 59.

[19] Chen X , Qi M , Yang Q , et al. MiR-299-3p functions as a tumor suppressor in thyroid cancer by regulating SHOC2. Eur Rev Med Pharmacol Sci 2019; 23: 232- 40.

[20] Tan M , Chang Y , Liu X , et al. The Sag-Shoc2 axis regulates conversion of mPanINs to cystic lesions in Kras pancreatic tumor model. Cell Rep 2022; 41: 111837.

[21] Siegel RL , Miller KD , Wagle NS , et al. Cancer statistics, 2023. CA Cancer J Clin 2023; 73: 17- 48.

[22] Villanueva A , Chiang DY , Newell P , et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 2008; 135: 1972- 83, 1983.e1.

[23] Bhat M , Sonenberg N , Gores GJ . The mTOR pathway in hepatic malignancies. Hepatology 2013; 58: 810- 8.

[24] Hu TH , Huang C-C , Lin P-R , et al. Expression and prognostic role of tumor suppressor gene PTEN/MMAC1/TEP1 in hepatocellular carcinoma. Cancer 2003; 97: 1929- 40.

[25] Khemlina G , Ikeda S , Kurzrock R . The biology of Hepatocellular carcinoma: implications for genomic and immune therapies. Mol Cancer 2017; 16: 149.

[26] Ortega-Molina A , Serrano M . PTEN in cancer, metabolism, and aging. Trends Endocrinol Metab 2013; 24: 184- 9.

[27] Subbiah IM , Falchook GS , Kaseb AO , et al. Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials. Oncotarget 2015; 6: 28453- 62.

[28] Horie Y , Suzuki A , Kataoka E , et al. Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. J Clin Invest 2004; 113: 1774- 83.

[29] Song MS , Salmena L , Pandolfi PP . The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol 2012; 13: 283- 96.

[30] Park EJ , Lee JH , Yu G-Y , et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 2010; 140: 197- 208.

[31] Schulien I , Hasselblatt P . Diethylnitrosamine-induced liver tumorigenesis in mice. Methods Cell Biol 2021; 163: 137- 52.

[32] Wang L , Wang W-L , Zhang Y , et al. Epigenetic and genetic alterations of PTEN in hepatocellular carcinoma. Hepatol Res 2007; 37: 389- 96.

[33] Chow LM , Baker SJ . PTEN function in normal and neoplastic growth. Cancer Lett 2006; 241: 184- 96.

[34] Terai H , Hamamoto J , Emoto K , et al. SHOC2 Is a critical modulator of sensitivity to EGFR-TKIs in non-small cell lung cancer cells. Mol Cancer Res 2021; 19: 317- 28.

[35] Min L , He B , Hui L . Mitogen-activated protein kinases in hepatocellular carcinoma development. Semin Cancer Biol 2011; 21: 10- 20.

[36] Saxton RA , Sabatini DM . mTOR signaling in growth, metabolism, and disease. Cell 2017; 168: 960- 76.

[37] Samatar AA , Poulikakos PI . Targeting RAS-ERK signalling in cancer: promises and challenges. Nat Rev Drug Discov 2014; 13: 928- 42.

[38] Mossmann D , Park S , Hall MN . mTOR signalling and cellular metabolism are mutual determinants in cancer. Nat Rev Cancer 2018; 18: 744- 57.

[39] Levin VA , Panchabhai SC , Shen Li , et al. Different changes in protein and phosphoprotein levels result from serum starvation of high-grade glioma and adenocarcinoma cell lines. J Proteome Res 2010; 9: 179- 91.

[40] Sancak Y , Peterson TR , Shaul YD , et al. The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science 2008; 320: 1496- 501.

[41] Zhang CS , Hardie DG , Lin SC . Glucose starvation blocks translation at multiple levels. Cell Metab 2020; 31: 217- 8.

[42] Ito Y , Sasaki Y , Horimoto M , et al. Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma. Hepatology 1998; 27: 951- 8.

[43] Schmidt CM , McKillop IH , Cahill PA , et al. Increased MAPK expression and activity in primary human hepatocellular carcinoma. Biochem Biophys Res Commun 1997; 236: 54- 8.

[44] Connor F , Rayner TF , Aitken SJ , et al. Mutational landscape of a chemically-induced mouse model of liver cancer. J Hepatol 2018; 69: 840- 50.

[45] Sole CV , Calvo FA , Alvarez E , et al. Clinical significance of VEGFR-2 and (1)(8)F-FDG PET/CT SUVmax pretreatment score in predicting the long-term outcome of patients with locally advanced rectal cancer treated with neoadjuvant therapy. Eur J Nucl Med Mol Imaging 2013; 40: 1635- 44.

RIGHTS & PERMISSIONS

The Author(s). Published by Oxford University Press on behalf of Higher Education Press.